Advances in graft-versus-host disease prevention strategies: latest updates from the 2022 ASH annual meeting

This review summarizes the significant advancements in prophylaxis against graft-versus-host disease (GvHD) presented at the 2022 ASH Annual Meeting. The use of innovative agents and regimens, along with the conventional prophylactic approach of combining post-transplant cyclophosphamide and anti-thymocyte globulin, were discussed. The innovative agents and regimens highlighted in this review include abatacept, the first FDA-approved drug for acute GvHD prophylaxis; RGI-2001, which promotes the expansion of regulatory T cells; and cell therapies such as Orca-T and Orca-Q. These advancements provide promising strategies and options for GvHD prevention, offering hope for improved post-transplant patient outcomes in terms of survival rates.

Automated summary

This review summarizes the significant advancements in prophylaxis against graft-versus-host disease (GvHD) discussed at the 2022 ASH Annual Meeting, including the use of innovative agents and regimens. Key advancements highlighted include abatacept, the first FDA-approved drug for acute GvHD prophylaxis, RGI-2001 that promotes regulatory T cell expansion, and cell therapies such as Orca-T and Orca-Q. These advancements offer promising strategies and options for GvHD prevention and may lead to improved post-transplant patient outcomes in terms of survival rates.